DUSP4 protects BRAF- and NRAS-mutant melanoma from oncogene overdose through modulation of MITF

MAPK inhibitors (MAPKi) remain an important component of the standard of care for metastatic melanoma. However, acquired resistance to these drugs limits their therapeutic benefit. Tumor cells can become refractory to MAPKi by reactivation of ERK. When this happens, tumors often become sensitive to...

Descripción completa

Detalles Bibliográficos
Autores principales: Gutierrez-Prat, Nuria, Zuberer, Hedwig L, Mangano, Luca, Karimaddini, Zahra, Wolf, Luise, Tyanova, Stefka, Wellinger, Lisa C, Marbach, Daniel, Griesser, Vera, Pettazzoni, Piergiorgio, Bischoff, James R, Rohle, Daniel, Palladino, Chiara, Vivanco, Igor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Life Science Alliance LLC 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9113946/
https://www.ncbi.nlm.nih.gov/pubmed/35580987
http://dx.doi.org/10.26508/lsa.202101235

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9113946/
https://www.ncbi.nlm.nih.gov/pubmed/35580987
http://dx.doi.org/10.26508/lsa.202101235

Ejemplares similares